Drug Discovery made in Switzerland: info event in Shanghai
Based on an innovative strategic partnership agreed between the Chinese President and the President of the Swiss Confederation in 2016, SWITZERLAND INNOVATION cordially invites you to the Drug Discovery Event at the Novartis Campus in Shanghai.
About the Event:
Drug discovery has come a long way from guess work to a structural and targeted approach to finding new and better remedies. In order to see the big picture and to develop new drugs, companies need to stay up to date about the latest discoveries in genomics, proteomics, structural or quantitative biology. The industry must translate the scientific efforts into a new innovative product.
At SWITZERLAND INNOVATION, such interdisciplinary collaborations between science and industry can flourish, thus finding keys and pathways to more precise medicine and bring drug discovery into a new era. Together with the Swiss Business Hub China, SWITZERLAND INNOVATION is committed to promote Switzerland as a location for R&D and innovation. International corporations such as Roche, Novartis, and Actelion (J&J), have their home base and global research centers in Switzerland. Other leading biotech and pharmaceutical companies — many of them from the US — including AC Immune, Alnylam, Amgen, Biogen, Bluebird, Fosun, Luye Pharma, Prothena, or Tesaro have chosen Switzerland as an R&D location. Together with Novartis and Roche as the incumbent players, they attract many highly skilled experts from all over the world.
14.00 – 14.30 Registration
14.30 – 15.30 Key note speaches: Prof. Christoph Hock and Prof. Michael Hennig
15.30 – 16.30 Panel Discussion
16.30 – 18.00 Networking
Professor Christoph Hock, MD
- Co-director of the Institute of Regenerative Medicine (IREM) at the University of Zurich
- Clinician and clinical trialsinvestigator
- Vice President for Medicine at University of Zurich
Prof. Hock is the co-founder and board member of Neurimmune. The biopharmaceutical company partnered its lead program in Alzheimer’s disease with Biogen in 2007 and developed a recombinant human monoclonal antibody targeting the neurodegenerative process in Alzheimer’s disease.
Professor Michael Hennig, PhD
- 20 years of drug discovery expertise from research management at F. Hoffmann – La Roche AG Basel.
- Guest Professor for structural biology at the University of Basel
- Structural biologist and senior Pharma drug discovery executive
- Entrepreneur, co-founder of leadXpro AG
Prof. Hennig is CEO and Chairman of the Board of the biotech company leadXpro AG, located at the Switzerland Innovation Park innovaare. The company is committed to structure and biophysical methods based drug discovery on membrane protein targets. Key areas of research include the use of large research facilities such as Swiss Light Source (SLS), Swiss Free Electron Laser (SwissFEL) and single particle cryo-electron microscopy (cryo-EM). leadXpro’s research activities are focused on the lead discovery for better cancer treatments and antibiotics with new mechanisms of action.